Skip to main content
logo
Actinium Pharmaceuticals, Inc. (ATNM)
NYSEAMERICAN: ATNM · Real-Time Price · USD
0.7974
+0.0104 (1.32%)
Aug 7, 2026, 4:00 PM EDT - Market closed

Actinium Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
35.090.09-0.081.031.14
Revenue Growth
----92.14%-9.96%-
Gross Profit
35.090.09-0.081.031.14
Selling, General & Admin
7.4115.2112.0813.33128.08
Research & Development
18.1221.1230.0538.6723.1418.03
Total Operating Expenses
25.5336.3442.125235.1326.11
Operating Income
9.56-36.25-42.12-51.92-34.1-24.96
Interest Income
1.752.363.883.11.090.19
Total Non-Operating Income (Expense)
1.752.363.883.11.090.19
Pretax Income
27.9-33.89-38.24-48.82-33.02-24.77
Net Income
11.31-33.89-38.24-48.82-33.02-24.77
Net Income to Common
11.31-33.89-38.24-48.82-33.02-24.77
Net Income Growth
------
Shares Outstanding (Basic)
313130272421
Shares Outstanding (Diluted)
313130272421
Shares Change
0.30%3.74%13.03%10.20%17.37%69.51%
EPS (Basic)
0.36-1.09-1.27-1.83-1.37-1.20
EPS (Diluted)
0.36-1.09-1.27-1.83-1.37-1.20
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-23.25-24.68-33.08-47.498.28-21
Free Cash Flow Growth
------
Free Cash Flow Per Share
-0.74-0.79-1.10-1.780.34-1.02
Gross Margin
100.00%100.00%-100.00%100.00%100.00%
Operating Margin
27.23%-40274.40%--64098.80%-3311.07%-2182.17%
Profit Margin
32.23%-37652.20%--60269.10%-3205.53%-2165.56%
FCF Margin
-66.25%-27426.70%--58627.20%803.69%-1835.58%
EBITDA
9.78-36.07-41.92-51.71-33.41-24.44
EBITDA Margin
27.87%-40082.20%--63843.20%-3243.20%-2136.36%
EBIT
9.56-36.25-42.12-51.92-34.1-24.96
EBIT Margin
27.23%-40274.40%--64098.80%-3311.07%-2182.17%
SEC Filings: 10-K · 10-Q